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From the Department of Urology, University of California School of Medicine, San Francisco, California 
A B S T R A C T 
We investigated the effects of intracavernous injection of a combination of acetylcholine (ACh) 
and vasoactive intestinal polypeptide (VIP) on the erectile response in eleven adult male dogs. The 
minimum dose of ACh which increased the intracavernous pressure in eight dogs varied from 0.2 to 
40 μg., and the minimum dose of V I P varied from 0.2 to 5 μg. When the minimum doses of ACh 
and V I P were injected simultaneously, a strong increase of intracavernous pressure (the mean 
increase was 102 cm. H 2 0 from the baseline level) and a sustained erection (mean 5 min.) were 
observed in all eight dogs. The effect of simultaneous injection of both drugs was not additive but 
synergistic. Pretreatment with VIP-antibody and atropine intracavernously suppressed the erectile 
response induced by cavernous nerve stimulation. 
VIP may increase the affinity of muscarinic receptors for ACh in canine corpus cavernosum 
because pretreatment with atropine alone before the simultaneous injection of ACh and V I P 
completely abolished the effect of the combination. We conclude that ACh and V I P may play a 
cooperative role in canine penile erection. 
K E Y W O R D S : acetylcholine, vasoactive intestinal peptide, penile erection, canine 
There are two types of local control in penile erection: 
neurological and humoral. I n either case, the key event is a 
relaxation of the smooth muscle of the corpus cavernosum. 1 
Neurological control suggests three types of autonomic nervous 
system effect on the smooth muscle: adrenergic (excitatory), 
cholinergic ( inhibitory) and non-adrenergic non-cholinergic 
(NANC) ( inhibitory) . Several groups of humoral agents have 
been proven to influence the tone of cavernous smooth muscle 
when injected intracavernously. 2 
The presence of cholinesterase-containing fibers, 3 muscarinic 
receptors4 and acetylcholine (ACh) synthesis and release in 
human corpus cavernosum 5 has been reported. Cholinesterase-
positive fibers were also demonstrated around the cavernous 
arteries and w i t h i n the cavernous smooth muscle i n the canine 
penis. 6 Vasoactive intestinal polypeptide (VlP)-immunoreac-
tive fibers have been reported to run parallel to cholinesterase-
positive fibers in human corpus cavernosum. 7 
Recently i t has been found that neuropeptides are often 
located in the same neurons as ACh. 8 The mechanism of 
interaction of peptides and non-peptides is better understood 
in vascular neuromuscular systems.9 Lundberg demonstrated 
that V I P increased the aff inity of muscarinic receptors for ACh 
i n cat submandibular glands. 1 0 I n this study we investigated 
the effect of a combination of ACh and V I P i n canine penile 
erection. 
M A T E R I A L S A N D M E T H O D S 
I n eleven adult male mongrel dogs (12 to 34 kg.), anesthesia 
was induced by acepromazine (0.2 mg./kg., B.W.) and ketamine 
(10 mg./kg., B.W.) subcutaneously. Sodium pentobarbital (45 
to 60 mg./hour) was administered intravenously to maintain 
an adequate level of anesthesia and spontaneous respiration. 
The animal was placed i n a supine position, and the bladder 
and prostate were exposed through a midline abdominal inc i ­
sion. The cavernous nerves were identified posterolateral^ to 
the prostate and bipolar cuff electrodes (Avery Laboratories, 
Accepted for publication February 10, 1992. 
* Requests for reprints: Diabetes Center, Tokyo Women's Medical 
College, Kawadacho 8-1, Shinjuku-ku, Tokyo, Japan 162. 
Farmingdale, N Y ) were placed around them for electrical st im­
ulation. The ipsilateral internal pudendal artery to the cavern­
ous nerves was exposed and an ultrasonic blood flow probe 
(Transonic Systems Inc., N.Y.) was placed around the internal 
pudendal artery to measure the blood flow to the penis. The 
entire penis was denuded, exposing both corpora cavernosa 
down to the ischial rami. Two 21-gauge scalp-vein needles were 
inserted into each corpus cavernosum, one proximally for i n ­
tracavernous pressure (ICP) recording and the other distally 
for intra-cavernous injection. Systemic arterial blood pressure 
was monitored via a 16-gauge cannula in the femoral artery. 
A l l fluid-filled lines were connected to Statham pressure trans­
ducers and a Grass polygraph for recording. 
To find the minimum dose that effectively increased ICP, 
varying doses of ACh and V I P were injected intracavernously 
while ICP, systemic blood pressure and pudendal arterial b}ood 
flow were measured in eight dogs (Nos. 1-8). The doses of ACh 
injected were: 0.2, 1, 2, 5, 10, 20 and 40 Mg. The doses of V I P 
injected into the same corpus were: 0.2, 0.5, 1, 2, 3, 4 and 5 
Between each cavernous injection there were intervals of ap­
proximately 15 minutes, which was enough time for ICP to 
return to the baseline level. Before each injection, one ml . 
saline was injected intracavernously in order to ascertain the 
ineffectiveness of previous injection. Then the experimentally 
determined min imum doses of V I P and ACh were injected 
simultaneously into the same corpus as before. 
Following these studies, we repeated the same injection of 
the ACh and V I P combination i n four dogs i n the same corpus 
(Nos. 1-4). Then, to examine the effect of atropine on the 
combination, 20 to 50 μg of atropine sulfate was injected two 
minutes before the ACh-VIP injection was repeated. 
To investigate the possibility that ACh and V I P could play 
a role as neuro-cotransmitters in canine penile erection, the 
erectile response induced by cavernous nerve st imulation was 
compared before and after the intracavernous simultaneous 
injection w i t h atropine (10 to 100 μg.) and VIP-antibody (300 
to 500 μg., 1:10 di lution in saline) in six dogs (Nos. 6-11). 
Neurostimulations were performed every 15 minutes and in 
each response we measured the peak ICP and the erection time 
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T A B L E 1. Effects of intracavernous simultaneous injection of ACh and VIP on canine penile erection 
Dose of Injection Baseline I n c r e a s e o f I C P * * Duration of Plateau 
A C h V I P I C P A C h V I P A C h + V I P ( I C P > 80 cm.H 2 0) 
(cm.H 2 0) (cm.H 2 0) (Seconds) 
0.5 3 16 24 16 124 170 
20 5 16 4 34 98 126 
10 1 36 4 36 104 300 
0.2 0.5 10 24 54 96 1200 
2 0.2 24 32 24 92 110 
0.5 0.5 4 16 28 106 200 
40 2 16 20 4 122 330 
10 4 30 14 4 70 24 
10 2 19 17 25 102 308 (mean) 
I C P = Intracavernous pressure, V I P = Vasoactive intestinal polypeptide, A C h = Acetylcholine,**: Increase of I C P means the rise from the baseline level to the 
peak of I C P . 
ACh 0.5 *VIP 3.0 μ$ 
ACh 0.5 //g 
VIP 3.0 μ§ 
F I G . 1. Representative recordings of erectile response to simulta­
neous injection of A C h and V I P . Both 0.5 Mg. A C h and 3 ßg. V I P alone 
raised I C P slightly. Simultaneous injection of A C h and V I P in same 
corpus induced an immediate, strong increase of I C P up to 140 cm. 






v ^ ^ a ^ f f i j a r 
ACh 0 .5 μg given at φ 
VIP 1.0 given a t | 
- - - - - - ACh 0.5 //g + V I P 1.0 //g given a t | 
Atropine 20 μς given at | & ACh 0.5 μο, + VIP 1.0 μς given at | 
F I G . 2. Representative recordings of I C P induced by A C h and V I P 
before and after atropine injection. Both 0.5 μβ. A C h and 1.0 μ%. V I P 
alone raised I C P slightly. First simultaneous injection of 0.5 μφ A C h 
and 1.0 μg. V I P increased I C P to 88 cm. H 2 0 and secondary injection 
with same doses to 100 cm. H 2 0 . Following these studies, synergistic 
effect of A C h and V I P was completely abolished with intracavernous 
pretreatment with 20 μ%. atropine. 
(defined as the period when ICP was 60% above the peak ICP 
induced by the neurostimulation before injection). Drugs used 
were acetylcholine chloride (Johnson and Johnson Co.), V I P 
(Sigma), atropine sulfate (LyphoMed., Inc.) and VIP-antibody 
(Peninsula Laboratories). 
R E S U L T S 
The minimum dose of ACh which increased ICP i n eight 
dogs varied from 0.2 to 40 μg. After the injection of ACh, ICP 
rose 4 to 32 cm. H 2 0 above the baseline level. The min imum 
dose of V I P which increased ICP varied from 0.2 to 5 μg. After 
the injection of V I P , ICP rose 4 to 54 cm. H 2 0 (mean 25 cm. 
H 2 0 ) . There was no change of systemic blood pressure, but 
blood flow increased slightly (2-3 ml . /minute) w i t h these doses 
of ACh and V I P . I n al l eight dogs, the combination of the 
minimum dose of ACh and V I P induced an immediate, strong 
increase of intracavernous pressure (mean 102 cm. H 2 0 from 
baseline level) and a sustained high pressure (100-140 cm. 
H 2 0 ) for a mean of 5 minutes (range 0.5 to 20 minutes) w i t h a 
ful l erection (table 1). There was no change of systemic blood 
pressure but a mean 61 percent (range 28 to 100 percent) 
increase of pudendal blood flow over the baseline level. A 
representative recording of ICP after the simultaneous injection 
of ACh 0.5 /ig. and V I P 3 μg. is presented i n figure 1 w i t h the 
result of each injection wi th ACh 0.5 μg. and V I P 3 alone. 
When we repeated the same injection of the ACh and V I P 
combination, nearly identical results were obtained in four dogs 
examined. Following these studies, we found that i n four dogs 
pretreatment of the same corpus cavernosum wi th atropine 
sulfate (20 or 50 μg.) completely inhibited the synergistic effect 
of the combination of ACh and V I P (figure 2). 
After intracavernous injection w i t h the combination of atro­
pine and VIP-antibody, the erectile response to neurostimula­
t ion was performed every 15 minutes. The maximum suppres­
sion of ICP was observed 12 to 90 minutes after the injection. 
There was a significant difference i n the peak level of ICP 
before the injection (148 ± 22 cm. H 2 0 , mean ± standard 
deviation) and after injection (106 ± 43 cm. H 2 0 ) in the 
response of maximum suppression (p =0.046). We also found a 
significant difference in the duration of ICP greater than 60% 
of the peak ICP before injection (65 ± 25 seconds) and after 
(31 ± 31 seconds) (p =0.012). Interestingly, there was no 
significant change in arterial flow (28 ± 28 ml. /minute before 
and 29 ± 30 ml . /minute after injection) (table 2). 
D I S C U S S I O N 
The minimum doses of ACh and V I P that increased ICP 
varied so much probably due to the interindividual difference, 
however, we observed a consistent, synergistic effect of simul­
taneous intracavernous injection of ACh and V I P on canine 
penile erection in all dogs studied. We found that the synergistic 
effect was atropine sensitive, suggesting an effect of V I P on the 
cholinergic mechanism, 
ACh can induce smooth muscle relaxation but does not relax 
the smooth muscle directly. 1 1 When ACh is injected intracav-
ernously, i t probably diffuses gradually into the sinusoids and 
mediates endothelium-derived relaxing factor (EDRF). E D R F 
is now known to be nitr ic oxide released from the endothelium 
of various vascular beds. 1 2 The receptor on endothelial cells for 
ACh may be muscarinic because pretreatment of the corpus 
cavernosum w i t h atropine inhibits the effect of exogenous ACh 
i n v i v o 6 , 1 3 and in v i t ro . 1 1 
On the other hand, i t has been suggested that V I P plays a 
major role as one of the N A N C transmitters i n penile erection 1 4 
and induces cavernous smooth muscle relaxation i n both in 
v ivo 1 5 as well as in v i t r o 1 6 studies. The combination of ACh and 
V I P injection probably plays a cooperative role through the 
muscarinic receptors on endothelial cells of the sinusoidal space 
in the corpus cavernosum, because the synergistic effect was 
completely abolished by atropine pretreatment. 
The precise mechanism of the cooperative relationship be­
tween ACh and V I P i n penile erection is st i l l unknown. How­
ever, i t has recently become clear that perivascular nerves 
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T A B L E 2. Penile response to stimulation before and after intracavernous injection with VIP-antibody and atropine 
Ε )osage of Inj. Peak of I C P Erection Time* Change of B F Time to 
VIP-ab Atropine Before After Before After Before After Max. Effect** 
(cm.H 2 0) (Seconds) (ml./min.) (Minutes) 
300 100 120 44 48 0 17 16 12 
300 40 180 84 56 0 9 4 40 
500 10 136 84 54 12 20 21 90 
500 100 146 136 114 68 28 38 58 
500 100 168 160 69 64 85 84 72 
500 40 136 128 50 42 9 8 40 
Mean 148t 106t 65$ 31$ 28 29 
±SD ±22 ±43 ±25 ±31 ±28 ±30 
I C P = Intracavernous pressure, B F = Blood flow, VIP-ab = VIP-antibody. 
* Length of time that I C P is greater than 60% of the peak I C P before the injection. 
** The time from the point of injection to maximum effect, 
t Significant difference between 148 and 106 (p = 0.046). 
$ Significant difference between 65 and 31 (p = 0.012). 
contain a number of biologically active peptides, and amino 
acids i n addition to the classical neurotransmitters, ACh and 
noradrenaline. I n 1987, Burnstock proposed a mechanism of 
interaction between peptides and nonpeptides. 9 Some findings 
about the interaction of ACh and V I P i n parasympathetic 
nerves have been reported as follows: 
1) V I P increased the aff inity of the muscarinic receptor for 
ACh by about 10 5-fold in cat submandibular glands. 1 0 
2) Intravenously infused V I P decreased the ACh turnover 
rate by about 50% in rodent salivary glands. 1 7 
3) V I P increased the ACh synthesis, possibly by enhancing 
the activity of choline acetyltransferase in rat hippocam-
pal slices. 1 8 
I t can be speculated that V I P increases the aff inity of mus­
carinic receptors for ACh on the endothelial cells i n the corpus 
cavernosum and also reduces the ACh turnover rate, and thus 
plays a synergistic role w i t h ACh i n canine penile erection. 
The results in this study showed that the erectile response 
induced by cavernous nerve stimulation was suppressed by the 
intracavernous pretreatment w i t h atropine and VIP-antibody. 
The suppression is supposed to be due to the combination of 
the two drugs but not due to each drug alone because atropine 
modified only the response induced by neurostimulation, 6 and 
VIP-antibody blocked only the continuation of the response;1 5 
neither of them reduced the peak level of ICP. Although the 
time from injection to maximum suppression and the degree of 
suppression was not consistent in six dogs, the difference i n 
ICP before and after the injection was statistically significant 
(p <0.05). Andersson et al. suggested that erection in the dog 
is due to arterial vasodilation caused by V I P release, followed 
by a f i l l ing of the cavernous bodies under the control of the 
cholinergic mechanism and that both of these events have to 
occur to induce a ful l erection. 1 1 We propose that the interaction 
of ACh and V I P may play an important physiologic role i n 
canine penile erection. 
I n vivo experiments w i t h intracavernous injections of V I P i n 
monkeys and in humans have yielded contradictory resu l t s . 1 9 , 2 0 
Studies w i t h simultaneous injections of ACh and V I P i n mon­
keys and in men are planned. 
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